Safety Shot, Inc. (Nasdaq: SHOT), a wellness and dietary supplement company, has announced the publication of a peer-reviewed clinical trial in the Journal of Nutrition and Dietary Supplements. The trial results show statistically significant reductions in ethanol levels following acute alcohol intake. This implies the company's product can rapidly reduce alcohol levels in the body and prevent hangovers. The impact of this development on the company's financial performance will depend on factors such as market acceptance of the product and the company's pricing strategy.

Safety Shot Inc.'s shares traded lower after the company's CEO provided updates about its production, distribution, and revenue traction. The company launched its product, Sure Shot, on Amazon in November 2023 and on its own e-commerce channel in January 2024. Both launches reported high demand, indicating strong market interest in the product designed to enhance health and wellness. Safety Shot has also announced positive findings from a human clinical trial of Sure Shot.

Safety Shot, Inc. has projected a 50% increase in revenue for Q4 2024 compared to Q3 2024. This anticipated growth is attributed to the rebranding of its main product, strategic collaborations with retailers, and successful capital-raising strategies.

This section explains that while they strive to ensure the accuracy of their forward-looking statements, they cannot guarantee future results or achievements. Their financial statements are audited, prepared in accordance with the United States Generally Accepted Accounting Principles (GAAP), and are expressed in US dollars. The discussion that follows these statements contains plans, estimates, and beliefs that could vary significantly from actual results due to various factors. They do not plan to update their forward-looking statements to match actual results unless required by law.

1) Brief Summary: The company's performance appears to be struggling with a negative return on equity (ROE) and a significant year-over-year sales decline. The company's short-term performance is also bearish with a negative monthly and quarterly performance. Moreover, the company has a high beta, suggesting it's significantly more volatile than the market. However, the company has shown a substantial sales growth over the past 5 years and a positive sales growth quarter over quarter. 2) MARKET_SCORE: Given the negative ROE, declining sales, and poor short-term performance, it's challenging to predict an upward move. However, the notable sales growth over the past 5 years and positive Q/Q sales growth suggests some potential. Therefore, I would cautiously give a MARKET_SCORE: 40

. 3) PRICE_TARGET: Given the current market conditions and the company's financials, I would not suggest a high price target. Given the current price of $0.4464, a modest 10% increase could be a reasonable target. Thus, PRICE_TARGET: $0.49

. 4) AI_RPT_HEADLINE: "Struggling Company Shows Glimmer of Hope with Positive Q/Q Sales Growth."

-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes

====================================================== : 2025-04-02 18:25:42

# Analysis Completed Elapsed Time: 30.01 seconds